GSK plc Buys Back Own Shares
Ticker: GLAXF · Form: 6-K · Filed: May 29, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | May 29, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-buyback, transaction
TL;DR
GSK is buying back its own stock via Citigroup.
AI Summary
GSK plc announced on May 29, 2025, that it purchased a number of its own ordinary shares through its corporate stockbroker, Citigroup Global Markets Limited. The filing does not specify the exact number of shares or the total dollar amount involved in these transactions.
Why It Matters
Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share.
Risk Assessment
Risk Level: low — This filing is a routine report of share transactions and does not contain significant new financial or strategic information.
Key Players & Entities
- GSK plc (company) — Registrant
- Citigroup Global Markets Limited (company) — Corporate stockbroker
- May 2025 (date) — Reporting period
- 20250529 (date) — Filing date
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K filing is a report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, specifically detailing a transaction in GSK plc's own shares.
Who is acting as GSK's corporate stockbroker for these share purchases?
GSK is acting through its corporate stockbroker, Citigroup Global Markets Limited.
What type of shares did GSK purchase?
GSK purchased its own ordinary shares of 31¼ pence each.
Does the filing specify the number of shares purchased?
No, the filing states that GSK purchased 'the following number of the Company's ordinary shares' but the specific number is not detailed in the provided text.
What is GSK's principal executive office address?
GSK's principal executive office is located at 79 New Oxford Street, London, WC1A 1DG.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on May 29, 2025 regarding GSK plc (GLAXF).